Overview

The purpose of this study is to characterize immune cells using single-cell transcriptomic analysis in pediatric patients aged 2 to 18 years undergoing general anesthesia who are expected to receive Rocuronium, a non-depolarizing neuromuscular blocking agent, in the event of an allergic reaction.

Eligibility

Inclusion Criteria:

• Pediatric patients between the ages of 2 and 18 undergoing general anesthesia and surgery using the neuromuscular blocker, rocuronium.

Exclusion Criteria:

• Patients who have received immunomodulators, immunosuppressants, etc.
• Patients with autoimmune diseases (rheumatoid arthritis, lupus, Behcet's disease, etc.)
• Patients who regularly take, or have taken within 4 weeks, medications that may affect the immune system (oral steroids, anti-inflammatories, etc.)
• Other cases where the Principal Investigator determines that it is difficult to conduct the study.